CSJ 148

Drug Profile

CSJ 148

Alternative Names: CSJ-148; LJP538; LJP539

Latest Information Update: 12 Oct 2015

Price : $50

At a glance

  • Originator Humabs BioMed
  • Developer Novartis
  • Class Cytomegalovirus vaccines
  • Mechanism of Action Simplexvirus glycoprotein B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cytomegalovirus infections

Most Recent Events

  • 01 Jun 2015 Phase-I/II clinical trials in Cytomegalovirus infections prevention in Taiwan, Singapore, South Korea, Germany, Belgium, USA (unspecified route) (NCT02268526; EudraCT2014-002150-39)
  • 20 Jan 2015 Novartis plans a phase I/II trial for Cytomegalovirus infections prevention in Germany (unspecified route) (NCT02268526)
  • 27 Oct 2014 Preclinical trials in Cytomegalovirus infections prevention in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top